STAT3 and primary effusion lymphoma: In conclusion, the results obtained in this study suggest that the use of 5-AZA could upregulate the expression of STAT3 inhibitors such as SOCS3 and PTPN6/SHP1, reduce the activation of STAT3 and the expression of its pro-survival targets, and impair the survival of PEL cells.